Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE (glatiramer acetate injection) 40mg/mL

04-02-2014 Business Wire HealthComments (0)

PharmaceuticalTeva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental new drug application (sNDA) for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE. This new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of multiple sclerosis (MS). In addition to the newly approved dose, daily COPAXONE 20 mg/mL

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top